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Biotherapeutics are currently the fastest growing group of
pharmaceuticals, being a treatment option for a variety of
chronic and sometimes life-threatening conditions. They
represent a diverse group of biological products that broadly
encompasses nucleic acids, proteins, whole cells, viral par-
ticles, and vaccines. In recent years, great strides have been
made towards the development of safer and more effective
biotherapeutics, as well as in the adoption of cost-effective,
more efficient, and streamlined manufacturing processes.
This trend is expected to accelerate in the forthcoming years,
as emerging fields related to advanced therapies or personal-
izedmedicinemature. Despite these progresses, there are still
knowledge gaps across all stages of development, as well as
technical and regulatory hurdles that can thwart the approval
process of these products.
In this special issue, we are pleased to present a collection
of papers covering relevant aspects in the field of biothera-
peutics.
The work by T. Lin et al. focuses on cell-penetrating pep-
tides (CPPs). These generally correspond to short basic and
amphipathic peptides, with a demonstrated capacity of cross-
ing cell membranes, thereby facilitating the delivery of dif-
ferent types of cargoes such as nucleic acids, peptides,
proteins, small molecules, and nanoparticles. The authors
describe the use of the J-domain of the Heat Shock Protein 40
to enhance the transduction efficiency of arginine-rich CPPs
and suggest the internalization of the latter to take place via
macropinocytosis followed by endosomal escape.
Q. Chen and H. Lai review the recent progress in the
methodology of agroinfiltration as a solution to overcome
the challenge of transgene delivery into plant cells for large-
scale manufacturing of recombinant proteins. The authors
provide a general overview of gene deliverymethodologies in
plants, followed by a detailed description of agroinfiltration,
its applications and scalability, typical vectors used, and how
it can be used in differentNicotiana and non-Nicotiana hosts.
In the work by F. C. Mariz et al., the development
of an intellectual property- (IP-) free platform for human
papillomavirus (HPV) 16 L1 protein expression based on
the constitutive expression of the PGK1 promoter of the
methylotrophic yeast Pichia pastoris is reported. The authors
also claim to have achieved the intracellular assembly of HPV
VLPs in yeast cells for the first time.
S. Fujimaki et al. present us with a thorough review of
diabetes mellitus-related changes occurring in the central
nervous system and skeletal muscle, particularly in terms of
dysfunctional neural stem cells and satellite cells.The authors
discuss the beneficial effects of exercise in the prevention
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and therapy of diabetes, as well as the use of stem cell-based
approaches in the context of diabetes treatment.
Due to the complexity of many biologics, the assess-
ment of “equivalence” for products obtained from different
manufacturers currently presents a new set of challenges to
regulatory agencies, since it is not perfectly clear how similar
the biosimilar trastuzumab and its licensed equivalent need
to be in terms of physicochemical properties for granting a
marketing authorization. To illustrate the complexity of this
process C. A. Lo´pez-Morales et al. used a hierarchical stra-
tegy with an orthogonal approach to compare a biosimilar
trastuzumab to its reference product in terms of physico-
chemical and biological attributes.
Finally, J. Zurdo et al. present us with an in-depth review
of key aspects that need to be taken into consideration during
the development of biotherapeutics, such as those related
with the proper definition of a quality by design (QbD)
workflow, developability methodologies and risk assessment,
and product safety and validation.The authors then illustrate
the application of developability tools and strategy described
in practical case studies.
Collectively, these papers provide a comprehensive view
on the current advances taking place in the broad field of bio-
therapeutics and on the exciting challenges that lie ahead.
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